Astragaloside IV treatment is associated with caecal microbial differences without an observed reduction in high-choline-associated plasma TMAO: a pilot mouse study
Background Astragaloside IV (AS-IV) has reported anti-atherosclerotic effects and may alter the gut microbiota, but its relationship to the microbial choline–trimethylamine (TMA)–trimethylamine-N-oxide (TMAO) axis remains unclear. Methods In this exploratory pilot, twelve male C57BL/6J mice were assigned to Control, 1% choline (Model), or 1% choline plus AS-IV (40 mg/kg/day) groups (n = 4 each) for 28 days. Caecal 16S rRNA profiles, plasma choline/TMA/TMAO, and a sensitivity-tested CutC docking analysis were evaluated. The four mice in each group shared one cage, so cage and treatment were completely confounded. Results Bray–Curtis community composition differed among groups (PERMANOVA R2 = 0.619, P = 0.001), although the small sample and one-cage-per-group design preclude population-level or causal inference. High-choline exposure was associated with a 10.7-fold higher mean plasma TMAO than Control (668.3 vs. 62.3 ng/mL); mean TMAO remained high with AS-IV (709.8 ng/mL; AS-IV vs. Model P = 1.000). TMA and choline showed similar group patterns, but several measurements exceeded the vendor-reported quantification range and are exploratory. Taxonomic functional predictions were hypothesis-generating only. Docking scores for AS-IV and cycloastragenol were strongly dependent on search-box size and were not interpreted as evidence for or against CutC inhibition. Conclusion AS-IV treatment was associated with a different caecal microbial composition without an observed reduction in high-choline-associated plasma TMAO. These findings generate hypotheses but require replication in a powered, multi-cage study including both sexes and direct functional measurements.
Authors
- Zhou Qingyun (ORCID: https://orcid.org/0000-0001-9956-4719)
- Yanling Zhou
- Xiaolong Shu
Institutions
- Ningbo Medical Center Lihuili Hospital (CN)
- Chengdu University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-11-12
- DOI
- https://doi.org/10.3389/fphar.2026.1955228
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 0.00